Equities research analysts expect that RedHill Biopharma Ltd – (NASDAQ:RDHL) will report $1.89 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for RedHill Biopharma’s earnings, with the highest sales estimate coming in at $1.98 million and the lowest estimate coming in at $1.80 million. RedHill Biopharma posted sales of $100,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 1,790%. The business is expected to issue its next quarterly earnings results before the market opens on Thursday, February 22nd.
On average, analysts expect that RedHill Biopharma will report full-year sales of $1.89 million for the current fiscal year, with estimates ranging from $3.81 million to $3.98 million. For the next year, analysts anticipate that the firm will post sales of $45.40 million per share, with estimates ranging from $8.80 million to $113.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for RedHill Biopharma.
A number of research analysts recently issued reports on the stock. Roth Capital lowered their target price on shares of RedHill Biopharma from $27.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of RedHill Biopharma in a research note on Tuesday, November 21st. Zacks Investment Research lowered shares of RedHill Biopharma from a “buy” rating to a “hold” rating in a research note on Friday, November 24th. Finally, Nomura assumed coverage on shares of RedHill Biopharma in a research note on Friday, January 26th. They issued a “buy” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $20.58.
RedHill Biopharma (RDHL) opened at $6.12 on Tuesday. RedHill Biopharma has a twelve month low of $4.30 and a twelve month high of $11.25. The firm has a market cap of $130.19, a price-to-earnings ratio of -2.27 and a beta of 0.59.
Large investors have recently bought and sold shares of the stock. Creative Planning acquired a new position in RedHill Biopharma in the 4th quarter valued at $722,000. Bank of New York Mellon Corp grew its position in RedHill Biopharma by 13.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 12,005 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 1,440 shares during the last quarter. Family Management Corp grew its position in RedHill Biopharma by 46.6% in the 3rd quarter. Family Management Corp now owns 37,750 shares of the biotechnology company’s stock worth $408,000 after purchasing an additional 12,000 shares during the last quarter. Meitav Dash Investments Ltd. acquired a new stake in RedHill Biopharma in the 4th quarter worth $244,000. Finally, 683 Capital Management LLC acquired a new stake in RedHill Biopharma in the 4th quarter worth $5,136,000. Institutional investors and hedge funds own 8.82% of the company’s stock.
RedHill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.